In a public health advisory issued on March 30, 2007, Swiss pharmaceutical manufacturer Novartis agreed to withdraw Zelnorm (tegaserod maleate) from the U.S. market.

This action was taken, at the FDA's request, after Zelnorm was linked to a higher risk of heart attack and stoke. Further analyses of multiple clinical studies have shown Zelnorm to be associated with rare but life-threatening cardiovascular events.

Patients taking Zelnorm are advised to stop this medication immediately. Patients are counseled to maintain a high fiber diet, consider the use of a daily fiber supplement and utilize "over-the-counter" remedies for constipation, if necessary. Patients are encouraged to schedule an appointment with their gastroenterologist or primary care provider to discuss additional treatment options.

Unfortunately, due to the number of patients affected and the volume of patient phone calls regarding this recent development, AAGA physicians are unable to personally respond to each patient phone call.

Offices in Annapolis and Severna Park
"Setting the Standard for Gastroenterology"

Call 410.224.2116 · 1.866.224.AAGA